CELG Celgene Corporation
12,736
| Market Cap | $0.00 |
| 52-Wk High | $0.00 |
| 52-Wk Low | $0.00 |
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...Business Wire • about 9 hours ago
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite InstabilityHigh or Mismatch Repair...
Share to Feed
Bristol Myers Squibb (NYSE: BMY) today announced that on December 6, 2023, its Board of Directors authorized the repurchase of an additional $3 billion of the companys common stock under the companys...
Bristol-Myers Squibb (NYSE:BMY Get Free Report) declared a quarterly dividend on Wednesday, December 6th, RTT News reports. Investors of record on Friday, January 5th will be paid a dividend...
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The...
Related Stocks: BMY...
Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better...
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology Avidity Biosciences...
Summit Financial LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY Free Report) by 5.1% in the second quarter, according to its most recent disclosure with the Securities...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Latest CELG News
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
Business Wire • about 9 hours ago
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
Business Wire • about 10 hours ago
Bristol-Myers Squibb (NYSE:BMY) Raises Dividend to $0.60 Per Share
Ticker Report • about 20 hours ago